Clinical Trials Logo
  1. Home
  2. Diabetic Retinopathy
  3. NCT00864838
  4. Details
NCT00864838 Clinical Trial

Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab

Diabetic Retinopathy Clinical Trial

Official title:
Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00864838
Other study ID # 4429/2008
Secondary ID
Status Completed
Phase Phase 2
First received March 18, 2009
Last updated March 18, 2009
Start date June 2008
Est. completion date March 2009

Study information
Verified date March 2009
Source University of Sao Paulo
Contact n/a
Is FDA regulated No
Health authority Brazil: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.

Recruitment information / eligibility
Status Completed
Enrollment 56
Est. completion date March 2009
Est. primary completion date February 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of age related macular disease or diabetic retinopathy

- Able and willing to provide informed consent

Exclusion Criteria:

- History of ocular hypertension or glaucoma

- High Myopes (> 6 spherical diopters)

- High Hyperopes (> 4 spherical diopters)

- Pulmonary disease

- Renal disease

- Known allergy to any component of the study drug

- Myocardial infarction, transient ischemic attack within 4 months prior to randomization or any contraindication for bevacizumab use

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Acetazolamide
250 mg 1 hour before intravitreal injection
• Brimonidine tartarate
1 drop 1 hour before intravitreal injection
Procedure:
• Anterior chamber paracentesis
Immediately after bevacizumab injection

Locations
Country Name City State
n/a

Sponsors (2)
Lead Sponsor Collaborator
University of Sao Paulo Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP

Outcome
Type Measure Description Time frame Safety issue
Primary Intraocular pressure (mmHg) 1 hour and, 3 minutes before IVI. 3,10,20, 30 minutes after IVI Yes
See also
  Status Clinical Trial Phase
Completed NCT03660384 - Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy N/A
Completed NCT03660371 - ILM Peeling in PDR Patients Undergoing PPV for VH N/A
Completed NCT03660345 - PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME Phase 3
Completed NCT04905459 - ARDA Software for the Detection of mtmDR
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT05022615 - Comparing 3 Imaging Systems
Completed NCT00385333 - Metabolic Mapping to Measure Retinal Metabolism Phase 2
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Completed NCT03702374 - Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy Phase 3
Completed NCT01908816 - An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Phase 3
Completed NCT04009980 - Long-term Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus. N/A
Completed NCT02924311 - Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
Not yet recruiting NCT06257082 - Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities N/A
Not yet recruiting NCT05452993 - Screening for Diabetic Retinopathy in Pharmacies With Artificial Intelligence Enhanced Retinophotography N/A
Withdrawn NCT02812030 - Aflibercept for Retinopathy in the Real World N/A
Completed NCT02391558 - Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography N/A
Active, not recruiting NCT02330042 - OCT Biomarkers for Diabetic Retinopathy
Active, not recruiting NCT02353923 - OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A